EFFECT OF LORACARBEF AND AMOXICILLIN ON THE OROPHARYNGEAL AND INTESTINAL MICROFLORA OF PATIENTS WITH BRONCHITIS
EFFECT OF LORACARBEF AND AMOXICILLIN ON THE OROPHARYNGEAL AND INTESTINAL MICROFLORA OF PATIENTS WITH BRONCHITIS
复制标题
DOI：
10.3109/00365549409011783
复制
发表时间：
1994-01-01
影响因子：
--
通讯作者：
VERHOEF, J
中科院分区：
文献类型：
--
作者：
FLOOR, M;VANAKKEREN, F;VERHOEF, J
对口咽和肠道微生物菌群的影响以及劳拉卡比（200 mg b.i.d.）的疗效和耐受性。7天）与阿莫西林（500 mg t.i.d.对80例支气管炎患者进行比较。阿莫西林组18%的患者和劳拉卡比组5%的患者的口咽部样本在第8-10天左右显示了一种新的革兰氏阴性菌。在第8-10天，阿莫西林治疗组38%的患者粪便中存在基线时未发现的其他需氧菌，而劳拉卡比组为31%。治疗后，在劳拉卡比组的粪便样本中没有发现对劳拉卡比或阿莫西林耐药的需氧革兰氏阴性菌，而对阿莫西林或劳拉卡比耐药的（E。35%的患者接受阿莫西林治疗（P
The effect on the oropharyngeal and intestinal microflora and the efficacy and tolerance of loracarbef (200 mg b.i.d. for 7 days) versus amoxicillin (500 mg t.i.d. for 7 days) were compared in 80 patients with bronchitis. The oropharyngeal samples of 18% of patients in the amoxicillin group and 5% of patients in the loracarbef group revealed a new Gram-negative species around days 8-10. The presence of other aerobic bacteria than found at baseline in the faeces occurred in 38% of patients treated with amoxicillin compared with 31% in the loracarbef group on days 8-10. After treatment, no loracarbef- or amoxicillin-resistant aerobic Gram-negative bacteria were found in faecal samples in the loracarbef group, while amoxicillin- or loracarbef-resistant (E. coli) strains appeared in 35% of patients receiving amoxicillin (p